13.9  -0.11 (-0.79%)		04-24 12:51
Open: 14.07 High: 14.1725 Volume: 13,978		Pre. Close: 14.01 Low: 13.71 Market Cap: 394(M)

Short term
Mid term
Targets	6-month :	16.78	1-year :	18.42
Resists	First :	14.37	Second :	15.77
Pivot price	14.08
Supports	First :	12.1	Second :	10.06
MAs	MA(5) :	13.98	MA(20) :	13.84
	MA(100) :	13.08	MA(250) :	8.77
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	49.5	D(3) :	50.8
RSI	RSI(14): 49.5
52-week	High :	18.14	Low :	3.79

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NPCE ] has closed above bottom band by 43.5%. Bollinger Bands are 19.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	14.52 - 14.58	14.58 - 14.64
Low:	13.46 - 13.52	13.52 - 13.58
Close:	13.91 - 14.01	14.01 - 14.1

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Tue, 23 Apr 2024
Insider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 24,609 Shares of Stock - MarketBeat

Thu, 18 Apr 2024
NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $36,879.38 in Stock - MarketBeat

Mon, 15 Apr 2024
OrbiMed Advisors sells over $7 million in NeuroPace stock By Investing.com - Investing.com

Fri, 12 Apr 2024
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load? - Simply Wall St

Thu, 07 Mar 2024
NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call Transcript - Yahoo Finance

Thu, 07 Mar 2024
Neuropace, Inc.'s New Economy & Political Environment Risk – A Cause for Worry? - TipRanks.com - TipRanks

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	28 (M)
Shares Float	11 (M)
Held by Insiders	3.9 (%)
Held by Institutions	79.1 (%)
Shares Short	86 (K)
Shares Short P.Month	50 (K)

EPS	-1.27
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.74
Profit Margin	-50.4 %
Operating Margin	-28.1 %
Return on Assets (ttm)	-15.4 %
Return on Equity (ttm)	-119 %
Qtrly Rev. Growth	40.7 %
Gross Profit (p.s.)	0
Sales Per Share	2.3
EBITDA (p.s.)	-0.96
Qtrly Earnings Growth	0 %
Operating Cash Flow	-20 (M)
Levered Free Cash Flow	-12 (M)

PE Ratio	-10.97
PEG Ratio	0
Price to Book value	18.81
Price to Sales	6.03
Price to Cash Flow	-20.03

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.